Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,050.00. The company’s shares closed yesterday at $906.54.

According to TipRanks, Bansal is a 4-star analyst with an average return of 6.5% and a 55.12% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Bristol-Myers Squibb.

In addition to Wells Fargo, Regeneron also received a Buy from TD Cowen’s Tyler Van Buren in a report issued yesterday. However, on April 17, Cantor Fitzgerald maintained a Hold rating on Regeneron (NASDAQ: REGN).

REGN market cap is currently $99.59B and has a P/E ratio of 26.11.

Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year. Most recently, in February 2024, George Sing, a Director at REGN sold 1,000.00 shares for a total of $992,500.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron (REGN) Company Description:

Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.